Global Breast Cancer Drugs Market Overview 2024, Forecast To 2033
9 Jan, 2024
Experiencing strong momentum, the breast cancer drugs market is set to grow from $36.42 billion in 2023 to $39.63 billion in 2024, boasting a CAGR of 8.8%. Historical growth owes itself to increasing cancer incidence, R&D advancements, early detection, and evolving treatment guidelines. The forecast is promising, predicting a surge to $54.7 billion in 2028, driven by factors like an aging population, emerging markets, supportive policies, and notable trends in personalized medicine and clinical trials.
Global Breast Cancer Drugs Market Key Driver
The breast cancer drug market is expanding as breast cancer remains the most common cancer among women. In 2021, there were 284,200 new cases and 44,130 deaths. Factors like heredity, age, and lifestyle contribute, with developed countries experiencing higher rates. The increasing number of diagnoses propels the demand for breast cancer drugs, fostering market growth.
Get A Free Sample Of The Global Breast Cancer Drugs Market ReportGlobal Breast Cancer Drugs Market Segments
The breast cancer drugs market covered in this report is segmented –
1) By Type: Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels
3) By End User: Amubulatory, Hospitals, Clinics, Other End-Users
By Geography: The regions covered in the breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the breast cancer drugs market in 2023. The Middle East is expected to be the fastest-growing region in the breast cancer drugs market during the forecast period. The regions covered in the breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Breast Cancer Drugs Industry Players
F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC, Eli Lilly and Company Inc., Biocon Limited, Merck & Co. Inc., Genzyme Corporation, Johnson & Johnson, MacroGenics Inc., Celldex Therapeutics Inc., Onyx Pharmaceuticals Inc., BioNumerik Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., OncoGenex Pharmaceuticals Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Apthera Inc., Oncothyreon Inc., BiPar Sciences Inc., Puma Biotechnology Inc., Sanofi S.A., Genentech Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Accord Healthcare Limited, Alkem Laboratories Limited, Natco Pharma Limited, Fresenius Kabi AG, Lupin Limited, Glenmark Pharmaceuticals Limited
Get The Full Global Breast Cancer Drugs Market Report
Breast Cancer Drugs Market Overview
Breast cancer drugs refer to anti-cancer medications that can be taken orally or intravenously (injected into a vein). The majority of the body's cancer cells are reached by the medications via the bloodstream. Chemotherapy may occasionally be administered directly into this region if cancer has spread to the spinal fluid, which surrounds and protects the brain and spinal cord (called intrathecal chemotherapy).
Breast Cancer Drugs Global Market Report 2023 provides data on the global breast cancer drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The breast cancer drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.